title: A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.
abstract: BACKGROUND
  Although the occurrence of acute myeloid leukemia (AML) after chemotherapy for multiple myeloma (MM) is common in clinical settings, the simultaneous occurrence of these malignancies in patients without previous exposure to chemotherapy is a rare event. Etiology, disease management, and clinical treatment remain unclear for this particular occurrence. To the best of our knowledge, this study is the first to report a case of simultaneous presentation of AML and MM after exposure to ultraviolet irradiation.
  
  
  METHODS
  We reported the case of a 73-year-old man (Han Chinese ethnicity) without previous medical history of AML and MM. The morphology and immunology of bone marrow cells confirmed the co-existence of AML and MM. Fluorescent in situ hybridization analysis of immunomagnetically separated abnormal plasma cells showed abnormal expression of the amplified RB-1, TP53, and CDKN2C (1p32). Cytogenetic analysis demonstrated Y chromosome deletion. After the patient was administered with bortezomib combined with cytarabine + aclarubicin + granulocyte colony-stimulating factor (CAG regimen), and evident curative effects were observed. The patient achieved and maintained complete remission for more than 6 months. Prior to the disease occurrence, the patient had received ultraviolet irradiation for 1 year and was detected with aberrant gene expression of RB-1, TP53, and CDKN2C (1p32). Nevertheless, the correlation of this phenomenon with the etiology of concurrent AML with MM remains unclear.
  
  
  CONCLUSIONS
  This study discussed the case of a patient diagnosed with AML concurrent with MM, who has no previous exposure to chemotherapy. This patient was successfully treated by bortezomib combined with CAG regimen. This study provides a basis for clinical treatment guidance for this specific group of patients and for confirmation of the disease etiology.
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. wanglq@sdu.edu.cn.
authors.forename: Wang
authors.initials: W
authors.lastname: Lu-Qun
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. haoli2003611@163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Hao
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. lixiangxin2118@sina.com.
authors.forename: Li
authors.initials: L
authors.lastname: Xiang-Xin
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. leefl9880@163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Fang-Lin
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. wangll9572@163.com.
authors.forename: Wang
authors.initials: W
authors.lastname: Ling-Ling
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. xlchen1999@163.com.
authors.forename: Chen
authors.initials: C
authors.lastname: Xue-Liang
authors.affiliation: Departmen of Heamatology, Qilu Hospital, Shandong University, 107# Wenhuaxi Road, Jinan, 250012, P R. China. houming@medmail.com.cn.
authors.forename: Hou
authors.initials: H
authors.lastname: Ming
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D012074:Remission Induction
chemical_list: D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin